Company / Cash & Equivalents
Bio Essence Corp Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.4K
FY2024
5-year range
$114 / $6.3K
FY2021-FY2024
Trend
+1102.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +1103% YoY in FY2024, a notable deviation from the 3-year average annual change of +990%.
Based on SEC 10-K filings.
$1,371 in FY2024 with a 3-year CAGR of +65.4%.
Declined from $6,262 to $1,371 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +65.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +65.4%, indicating consistent growth.
- In FY2024, cash & equivalents increased 1102.6% year-over-year.
Company context
Key Data Points
- High Piotroski F-Score: 9/9 (strong financial health signals)
- Altman Z-Score -11.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.4K | +1102.6% |
| FY2023 | $114 | -98.2% |
| FY2022 | $6.3K | +1966.7% |
| FY2021 | $303 | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026